ClinicalTrials.gg
CompletedNCT05113953Updated Sep 9, 2025Results posted

A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder

A Phase 2 interventional study of Centanafadine and Placebo in Binge-Eating Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 25 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies in Binge-Eating Disorder with a site in United States — 19 open to participants now, 26 under way, 2 of them phase 3. Binge-Eating Disorder · United States.

Enrollment
28th of 112
147 · median 67
Started
2021
with 4 others
Phase 2
14 of 122
1 open now
Registered
88th of 122
by date

Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 28th largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2021, is one of 14 in phase 2, and was the 88th registered.

Binge-Eating Disorder

233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.

Browse Binge-Eating Disorder studies →

Open to participants now

19 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Binge-Eating Disorder with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of 2 doses of centanafadine sustained-release (SR) (200 milligrams [mg] and 400 mg total daily dose [TDD]) compared with placebo in adults with moderate to severe binge eating disorder (BED).

03

Conditions studied

  • Binge-Eating Disorder

Browse trials for

Keywords

  • Centanafadine
  • Binge Eating Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants 18 to 65 years of age (inclusive) at the time of .
  • A primary diagnosis of BED, or is diagnosed at screening, according to - 5th Edition (DSM-5) criteria and confirmed by the Structured Clinical Interview for DSM-5 (SCID).
  • BED with a history of at least 2 binge eating days per week for 6 months prior to screening.
  • A rating of 4 or higher on the Clinical Global Impression - Severity (CGI-S) at screening and baseline.
  • (BMI) of 18 to 45 kg/m\^2, inclusive.

Exclusion criteria

Exclusion Criteria:

  • Lifetime history of bulimia nervosa or anorexia nervosa.
  • Participation in a formal weight loss program within 3 months of screening or planning to start a weight loss program during the trial.
  • History of bariatric surgery.
  • Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 18.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Centanafadine 400 mg

    Participants will receive centanafadine 200 mg SR tablets, orally, twice daily (BID) at a TDD of 400 mg for 8 weeks.

    Drug: Centanafadine

  • Experimental
    Centanafadine 200 mg

    Participants will receive centanafadine 100 mg SR tablets, orally, BID at a TDD of 200 mg along with centanafadine matching placebo tablets, orally, BID for 8 weeks.

    Drug: Centanafadine · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will receive centanafadine matching placebo tablets, orally, BID for 8 weeks.

    Drug: Placebo

Interventions

  • Sustained-release oral tablets

  • DrugPlacebo

    Oral tablets

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Number of Binge Eating Days Per Week

    Binge eating day was defined as a day with at least one binge eating episode. Least squares (LS) mean was determined by Mixed-effect Model Repeated Measures (MMRM) method with change from baseline in binge eating days per week at scheduled visit as dependent variable and included fixed effect terms for treatment, trial center, visit week, and an interaction term of treatment by visit week.

    Time frame: Baseline, Weeks 7 to 8

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score

    The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on scale with a score range of 0 to 7 where, 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

    Time frame: Baseline, Week 8

  2. Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) Related to Rash, AEs Related to Abuse, and AEs Involving Medication Handling Irregularities (MHIs)

    An AE is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. AESIs were newly acquired skin eruptions that were non-traumatic which included eruptions such as skin rashes, skin irritations, skin reactions, or acneiform lesions. AEs related to abuse included: Feeling abnormal (floaty feeling in the head), euphoric mood (feeling high). MHIs included: IMP accounting errors, not involving suspected abuse nor diversion by participant; Non-compliance with trial procedures, not involving suspected abuse nor diversion by participant; and other cases involving neither suspected abuse nor diversion of trial IMP by participant.

    Time frame: From first dose of study drug up to 1 week post last dose (Up to 9 weeks)

  3. Number of Participants With Potentially Clinically Relevant Laboratory Abnormalities

    Laboratory assessments included hematology, serum chemistry, and urinalysis. Abnormality criteria included: In milligrams per deciliter (mg/dL) \[high bilirubin ≥2.0, low/high calcium ≤8.2/ ≥12, high cholesterol fasting ≥240, high glucose, fasting ≥100, high triglycerides, fasting ≥150, high urate ≥8.5 female / ≥10.5 male, high protein urine ≥2 units increase\]; high creatine kinase (units per liter \[U/L\]) \>3xupper limit of normal (ULN); high eosinophils/leukocytes ≥10%, low neutrophils/leukocytes ≤15%; In 10\^3/microliter (µL) \[low or high leukocytes ≤2.8x10\^9/L or ≥16.0x10\^9/L, low neutrophils ≤1.5x10\^9/L\]. The categories with at least one participant with clinically relevant value are reported here.

    Time frame: From first dose of study drug up to 1 week post last dose (Up to 9 weeks)

  4. Number of Participants With Potentially Clinically Relevant Vital Sign Abnormalities

    Vital sign measurements included heart rate in supine and standing positions (low: \<50 beats per minute \[bpm\] and decrease ≥10 bpm; High: \>100 bpm and increase ≥10 bpm), systolic blood pressure (BP) in supine and standing positions (low: \<90 millimeters of mercury \[mmHg\] and decrease ≥20 mmHg; High: ≥140 mmHg and increase ≥20 mmHg), diastolic BP in supine and standing positions (low: \<60 mmHg and decrease ≥10 mmHg; High: ≥90 mmHg and increase ≥10 mmHg), weight in kilograms (kg) (low: ≥7% decrease; High: ≥7% increase), orthostatic hypotension, (≥30mmHg decrease is systolic BP or ≥20 mmHg in diastolic BP after at least 3 minutes of standing compared to the previous supine BP), and orthostatic tachycardia (≥25 bpm increase in heart rate from supine to standing). The categories with at least one participant with clinically relevant value are reported here.

    Time frame: From first dose of study drug up to 1 week post last dose (Up to 9 weeks)

  5. Number of Participants With Potentially Clinically Relevant 12-Lead Electrocardiogram (ECG) Abnormalities

    12-lead ECG abnormality criteria included Rhythm: Supraventricular premature beat (not present at baseline and present post baseline); and Conduction: Primary (1°) atrioventricular block (PR ≥200 milliseconds \[msec\] and increase of ≥50 msec).

    Time frame: From first dose of study drug up to 1 week post last dose (Up to 9 weeks)

  6. Study Medication Withdrawal Questionnaire (SMWQ) Total Mean Score

    SMWQ is a questionnaire to assess withdrawal symptoms subsequent to completion of dosing with IMP. The SMWQ is a modification of the Amphetamine Withdrawal Questionnaire, in which in which the terms "amphetamines and methamphetamine" are replaced with the term "the study medication." This change was intended to prevent bias by implying that the trial medication might be an amphetamine or amphetamine-like stimulant when presented with the survey. This questionnaire comprises of 13 items which describe symptoms associated with the cessation of study medication use for which participants indicate severity on a scale with scores ranging from 0 (no withdrawal symptoms) to 4 (most severe withdrawal symptom). The total score is calculated as the sum of all the scores for the 13 items, ranging from 0 to 52. Lower scores indicate less withdrawal symptoms.

    Time frame: Week 8

  7. Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score

    The HAM-A scale assesses both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It consists of 14 items to rate the severity of symptoms of anxiety, each scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Total score was calculated as the sum of the 14 individual item scores, ranging from 0 to 56 and categorized as 0-13: normal range, 14-17: mild severity, 18-24: mild to moderate severity, 25-30: moderate to severe, and \>=31: severe. A higher score indicates a more severe anxiety.

    Time frame: Baseline, Week 8

  8. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a diagnostic questionnaire used by clinician to assess the participant's severity of depression. The questionnaire includes questions on ten symptoms: Apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, difficulty concentrating, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each question is scored on a range of 0 to 6 points and the total score was calculated as the sum of the 10 individual item scores, ranging from 0 to 60 categorized as: 0 to 6: normal/symptoms absent, 7 to 19: mild depression, 20 to 34: moderate depression, and 35 to 60: severe depression. Higher scores indicate increased depressive symptoms.

    Time frame: Baseline, Week 8

  9. Number of Participants With Suicidality as Measured by Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS is a clinician-administered instrument that systematically assess suicidal ideation (SI) and suicidal behavior rating scale. It rates an individual's degree of SI on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent). The scale identifies specific behaviors ranging from "preparatory acts or behavior" to "suicide" which may be indicative of an individual's intent to complete suicide. Suicidality was reported in this outcome measure, defined as at least 1 occurrence of suicidal ideation or at least 1 occurrence of suicidal behavior for each assessment period.

    Time frame: Week 8

Other outcomes

  1. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score

    The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on scale with a score range of 0 to 7 where, 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

    Time frame: Baseline, Weeks 1, 2, 3, 4, and 6

  2. Mean Clinical Global Impression - Change (CGI-C) Score

    The CGI-C is a single-item, 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to their baseline state at the beginning of treatment, rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. A higher score on the CGI-C represents a greater disease progression.

    Time frame: Week 8

  3. Change From Baseline in Yale-Brown Obsessive-Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Score

    The Y-BOCS-BE is a clinician-rated scale that assesses obsession with binge eating thoughts and compulsiveness of binge eating behaviors. The Y-BOCS-BE is a 10-item scale, divided into 2 subscales with 5 items each: obsessions and compulsions. Each item is rated from 0 (no symptoms) to 4 (extreme symptoms) and total scores range from 0 to 40. A score of 0 to 7 is considered sub-clinical; 8 to 15 as mild; 16 to 23 as moderate; 24 to 31 as severe; and 32 to 40 as extreme obsession and compulsiveness of binge eating. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

    Time frame: Baseline, Week 8

  4. Percentage of Participants With Four-Week Cessation From Binging

    Percentages are rounded off to the nearest single decimal point.

    Time frame: Week 8

  5. Change From Baseline in Number of Binge Episodes Per Week

    All binge eating episodes were recorded daily by the participant in a binge eating diary. At each visit, the investigator reviewed the completed diary and assessed the number of binges for each day. Number of binge episodes per week are reported. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

    Time frame: Baseline, Weeks 7 to 8

  6. Change From Baseline in Patient Global Impression - Severity (PGI-S) Score

    The PGI-S is a single-item self-report of the participant's severity of symptoms. Severity is rated on a 7-point scale: 1 = no symptoms; 2 = minimal; 3 = mild; 4 = moderate; 5 = marked; 6 = severe; 7 = very severe. A higher score indicates more severe symptoms. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

    Time frame: Baseline, Week 8

  7. Mean Patient Global Impression - Change (PGI-C) Score

    The PGI-C is a single-item, self-report that requires the participant to assess how much his/her illness has improved or worsened relative to baseline and rate on a 7-point scale: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. A higher score indicates a greater disease progression.

    Time frame: Week 8

  8. Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2): Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

    The SF-36 is a health-related survey that assesses participant's health status and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health, mental health, social functioning, and vitality. The 8 domains are combined to form 2 component scores: PCS and MCS. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health-related quality of life. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

    Time frame: Baseline, Week 8

  9. Change From Baseline in Eating Disorder Examination Questionnaire-7-Item Version (EDE-Q7) Total Score

    The EDE-Q7 is a self-report version of the eating disorder examination (EDE) and measures eating-disorder psychopathology in the past 28 days and over longer intervals. It comprises of 3 subscale scores (dietary restraint, shape/weight overvaluation, and body dissatisfaction). An EDE-Q global (total) score is calculated as average of 3 subscale scores and ranges from 0 (absence of the feature) to 6 (extreme degree). A higher score indicates a more severe outcome. LS mean was determined by ANCOVA model with treatment and trial center as fixed factors and baseline value as covariate.

    Time frame: Baseline, Week 8

07

Results

Posted Sep 9, 2025

Participant flow

Participants took part in this study at investigational sites in the United States from 22 December 2021 to 19 August 2022.

Participant flow — Overall Study
MilestoneCentanafadine 400 mgCentanafadine 200 mgPlacebo
Started494949
Safety analysis set494949
Efficacy analysis set494847
Completed363940
Not completed13109
Withdrew: Adverse event503
Withdrew: Lost to follow-up342
Withdrew: Non-compliance with study drug100
Withdrew: Withdrawal by subject264
Withdrew: Reason not specified200

Outcome measures

PrimaryChange From Baseline in Number of Binge Eating Days Per Week

Binge eating day was defined as a day with at least one binge eating episode. Least squares (LS) mean was determined by Mixed-effect Model Repeated Measures (MMRM) method with change from baseline in binge eating days per week at scheduled visit as dependent variable and included fixed effect terms for treatment, trial center, visit week, and an interaction term of treatment by visit week.

Time frame:
Baseline, Weeks 7 to 8
Reported as:
Least squares mean · binge eating days per week
Change From Baseline in Number of Binge Eating Days Per Week
binge eating days per weekCentanafadine 400 mgCentanafadine 200 mgPlacebo
Change From Baseline in Number of Binge Eating Days Per Week-3.44 ± 0.23-3.07 ± 0.23-3.01 ± 0.23
Statistical analysis
  • Centanafadine 400 mg vs Placebo · MMRM · p = 0.1893 (P-value was analysed by MMRM method with change from baseline in binge eating days per week at scheduled visit as dependent variable and included fixed effect terms for treatment, trial center, visit week, interaction term of treatment by visit week.) · Treatment difference: -0.42 · 95% CI -1.06 to 0.21
  • Centanafadine 200 mg vs Placebo · MMRM · p = 0.8502 (P-value was analysed by MMRM method with change from baseline in binge eating days per week at scheduled visit as dependent variable and included fixed effect terms for treatment, trial center, visit week, interaction term of treatment by visit week.) · Treatment difference: -0.06 · 95% CI -0.69 to 0.57
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score

The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on scale with a score range of 0 to 7 where, 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score
score on a scaleCentanafadine 400 mgCentanafadine 200 mgPlacebo
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score-2.15 ± 0.18-1.43 ± 0.18-1.61 ± 0.18
Statistical analysis
  • Centanafadine 400 mg vs Placebo · MMRM · p = 0.0313 (P-value was analysed by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.) · Treatment difference: -0.54 · 95% CI -1.02 to -0.05
  • Centanafadine 200 mg vs Placebo · MMRM · p = 0.4471 (P-value was analysed by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.) · Treatment difference: 0.19 · 95% CI -0.30 to 0.67
Other pre-specifiedChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score

The CGI-S is a standardized, clinician-administered global rating scale that measures disease severity on scale with a score range of 0 to 7 where, 0 = not assessed; 1 = normal, not at all ill; 2 = borderline ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. A higher score on the CGI-S represents a higher severity of disease. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

Time frame:
Baseline, Weeks 1, 2, 3, 4, and 6

Results for this outcome have not been posted.

Other pre-specifiedMean Clinical Global Impression - Change (CGI-C) Score

The CGI-C is a single-item, 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to their baseline state at the beginning of treatment, rated as: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. A higher score on the CGI-C represents a greater disease progression.

Time frame:
Week 8

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Yale-Brown Obsessive-Compulsive Scale Modified for Binge Eating (Y-BOCS-BE) Score

The Y-BOCS-BE is a clinician-rated scale that assesses obsession with binge eating thoughts and compulsiveness of binge eating behaviors. The Y-BOCS-BE is a 10-item scale, divided into 2 subscales with 5 items each: obsessions and compulsions. Each item is rated from 0 (no symptoms) to 4 (extreme symptoms) and total scores range from 0 to 40. A score of 0 to 7 is considered sub-clinical; 8 to 15 as mild; 16 to 23 as moderate; 24 to 31 as severe; and 32 to 40 as extreme obsession and compulsiveness of binge eating. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

Time frame:
Baseline, Week 8

Results for this outcome have not been posted.

Other pre-specifiedPercentage of Participants With Four-Week Cessation From Binging

Percentages are rounded off to the nearest single decimal point.

Time frame:
Week 8

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Number of Binge Episodes Per Week

All binge eating episodes were recorded daily by the participant in a binge eating diary. At each visit, the investigator reviewed the completed diary and assessed the number of binges for each day. Number of binge episodes per week are reported. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

Time frame:
Baseline, Weeks 7 to 8

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Patient Global Impression - Severity (PGI-S) Score

The PGI-S is a single-item self-report of the participant's severity of symptoms. Severity is rated on a 7-point scale: 1 = no symptoms; 2 = minimal; 3 = mild; 4 = moderate; 5 = marked; 6 = severe; 7 = very severe. A higher score indicates more severe symptoms. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

Time frame:
Baseline, Week 8

Results for this outcome have not been posted.

Other pre-specifiedMean Patient Global Impression - Change (PGI-C) Score

The PGI-C is a single-item, self-report that requires the participant to assess how much his/her illness has improved or worsened relative to baseline and rate on a 7-point scale: 1 = very much improved; 2 = much improved; 3 = minimally improved; 4 = no change; 5 = minimally worse; 6 = much worse; or 7 = very much worse. A higher score indicates a greater disease progression.

Time frame:
Week 8

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2): Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores

The SF-36 is a health-related survey that assesses participant's health status and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health, mental health, social functioning, and vitality. The 8 domains are combined to form 2 component scores: PCS and MCS. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. MCS consisted of social functioning, vitality, mental health, and role-emotional scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health-related quality of life. LS mean was determined by MMRM method with change from baseline value as dependent variable and included treatment, trial center, visit week, treatment-by-week interaction as fixed effects and baseline-by-week interaction as covariates.

Time frame:
Baseline, Week 8

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Eating Disorder Examination Questionnaire-7-Item Version (EDE-Q7) Total Score

The EDE-Q7 is a self-report version of the eating disorder examination (EDE) and measures eating-disorder psychopathology in the past 28 days and over longer intervals. It comprises of 3 subscale scores (dietary restraint, shape/weight overvaluation, and body dissatisfaction). An EDE-Q global (total) score is calculated as average of 3 subscale scores and ranges from 0 (absence of the feature) to 6 (extreme degree). A higher score indicates a more severe outcome. LS mean was determined by ANCOVA model with treatment and trial center as fixed factors and baseline value as covariate.

Time frame:
Baseline, Week 8

Results for this outcome have not been posted.

SecondaryNumber of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) Related to Rash, AEs Related to Abuse, and AEs Involving Medication Handling Irregularities (MHIs)

An AE is defined as any untoward medical occurrence in a clinical trial participant administered an IMP and which does not necessarily have a causal relationship with this treatment. AESIs were newly acquired skin eruptions that were non-traumatic which included eruptions such as skin rashes, skin irritations, skin reactions, or acneiform lesions. AEs related to abuse included: Feeling abnormal (floaty feeling in the head), euphoric mood (feeling high). MHIs included: IMP accounting errors, not involving suspected abuse nor diversion by participant; Non-compliance with trial procedures, not involving suspected abuse nor diversion by participant; and other cases involving neither suspected abuse nor diversion of trial IMP by participant.

Time frame:
From first dose of study drug up to 1 week post last dose (Up to 9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Adverse Events of Special Interest (AESIs) Related to Rash, AEs Related to Abuse, and AEs Involving Medication Handling Irregularities (MHIs)
ParticipantsCentanafadine 400 mgCentanafadine 200 mgPlacebo
AEs342824
AESIs Related to Rash531
AEs Related to Abuse210
AEs Involving MHIs223
SecondaryNumber of Participants With Potentially Clinically Relevant Laboratory Abnormalities

Laboratory assessments included hematology, serum chemistry, and urinalysis. Abnormality criteria included: In milligrams per deciliter (mg/dL) \[high bilirubin ≥2.0, low/high calcium ≤8.2/ ≥12, high cholesterol fasting ≥240, high glucose, fasting ≥100, high triglycerides, fasting ≥150, high urate ≥8.5 female / ≥10.5 male, high protein urine ≥2 units increase\]; high creatine kinase (units per liter \[U/L\]) \>3xupper limit of normal (ULN); high eosinophils/leukocytes ≥10%, low neutrophils/leukocytes ≤15%; In 10\^3/microliter (µL) \[low or high leukocytes ≤2.8x10\^9/L or ≥16.0x10\^9/L, low neutrophils ≤1.5x10\^9/L\]. The categories with at least one participant with clinically relevant value are reported here.

Time frame:
From first dose of study drug up to 1 week post last dose (Up to 9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Laboratory Abnormalities
ParticipantsCentanafadine 400 mgCentanafadine 200 mgPlacebo
High Bilirubin (mg/dL)001
Low Calcium (mg/dL)010
High Cholesterol, Fasting (mg/dL)864
High Creatine Kinase (U/L)211
High Glucose, Fasting (mg/dL)7118
High Triglycerides, Fasting (mg/dL)6914
High Urate: Males and Females (mg/dL)010
High Eosinophils/Leukocytes (%)243
Low Leukocytes (10^3/µL)222
Low Neutrophils (10^3/µL)863
Low Neutrophils/Leukocytes (%)322
High Protein, Urine (mg/dL)181514
SecondaryNumber of Participants With Potentially Clinically Relevant Vital Sign Abnormalities

Vital sign measurements included heart rate in supine and standing positions (low: \<50 beats per minute \[bpm\] and decrease ≥10 bpm; High: \>100 bpm and increase ≥10 bpm), systolic blood pressure (BP) in supine and standing positions (low: \<90 millimeters of mercury \[mmHg\] and decrease ≥20 mmHg; High: ≥140 mmHg and increase ≥20 mmHg), diastolic BP in supine and standing positions (low: \<60 mmHg and decrease ≥10 mmHg; High: ≥90 mmHg and increase ≥10 mmHg), weight in kilograms (kg) (low: ≥7% decrease; High: ≥7% increase), orthostatic hypotension, (≥30mmHg decrease is systolic BP or ≥20 mmHg in diastolic BP after at least 3 minutes of standing compared to the previous supine BP), and orthostatic tachycardia (≥25 bpm increase in heart rate from supine to standing). The categories with at least one participant with clinically relevant value are reported here.

Time frame:
From first dose of study drug up to 1 week post last dose (Up to 9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant Vital Sign Abnormalities
ParticipantsCentanafadine 400 mgCentanafadine 200 mgPlacebo
Low Heart Rate Supine (bpm)100
High Heart Rate Supine (bpm)013
High Systolic BP Supine (mmHg)513
Low Diastolic BP Supine (mmHg)120
High Diastolic BP Supine (mmHg)613
High Heart Rate Standing (bpm)646
Low Systolic BP Standing (mmHg)100
High Systolic BP Standing (mmHg)324
Low Diastolic BP Standing (mmHg)110
High Diastolic BP Standing (mmHg)1036
Low Weight (kg)311
High Weight (kg)010
Orthostatic Hypotension (mmHg)231
Orthostatic Tachycardia (mmHg)854
SecondaryNumber of Participants With Potentially Clinically Relevant 12-Lead Electrocardiogram (ECG) Abnormalities

12-lead ECG abnormality criteria included Rhythm: Supraventricular premature beat (not present at baseline and present post baseline); and Conduction: Primary (1°) atrioventricular block (PR ≥200 milliseconds \[msec\] and increase of ≥50 msec).

Time frame:
From first dose of study drug up to 1 week post last dose (Up to 9 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Potentially Clinically Relevant 12-Lead Electrocardiogram (ECG) Abnormalities
ParticipantsCentanafadine 400 mgCentanafadine 200 mgPlacebo
Supraventricular Premature Beat010
1° Atrioventricular Block001
SecondaryStudy Medication Withdrawal Questionnaire (SMWQ) Total Mean Score

SMWQ is a questionnaire to assess withdrawal symptoms subsequent to completion of dosing with IMP. The SMWQ is a modification of the Amphetamine Withdrawal Questionnaire, in which in which the terms "amphetamines and methamphetamine" are replaced with the term "the study medication." This change was intended to prevent bias by implying that the trial medication might be an amphetamine or amphetamine-like stimulant when presented with the survey. This questionnaire comprises of 13 items which describe symptoms associated with the cessation of study medication use for which participants indicate severity on a scale with scores ranging from 0 (no withdrawal symptoms) to 4 (most severe withdrawal symptom). The total score is calculated as the sum of all the scores for the 13 items, ranging from 0 to 52. Lower scores indicate less withdrawal symptoms.

Time frame:
Week 8
Reported as:
Mean · score on a scale
Study Medication Withdrawal Questionnaire (SMWQ) Total Mean Score
score on a scaleCentanafadine 400 mgCentanafadine 200 mgPlacebo
Study Medication Withdrawal Questionnaire (SMWQ) Total Mean Score5.56 ± 4.807.72 ± 6.596.40 ± 6.47
SecondaryChange From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score

The HAM-A scale assesses both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). It consists of 14 items to rate the severity of symptoms of anxiety, each scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Total score was calculated as the sum of the 14 individual item scores, ranging from 0 to 56 and categorized as 0-13: normal range, 14-17: mild severity, 18-24: mild to moderate severity, 25-30: moderate to severe, and \>=31: severe. A higher score indicates a more severe anxiety.

Time frame:
Baseline, Week 8
Reported as:
Mean · score on a scale
Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score
score on a scaleCentanafadine 400 mgCentanafadine 200 mgPlacebo
Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Score-1.23 ± 3.760.55 ± 4.80-1.20 ± 4.22
SecondaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score

The MADRS is a diagnostic questionnaire used by clinician to assess the participant's severity of depression. The questionnaire includes questions on ten symptoms: Apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, difficulty concentrating, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each question is scored on a range of 0 to 6 points and the total score was calculated as the sum of the 10 individual item scores, ranging from 0 to 60 categorized as: 0 to 6: normal/symptoms absent, 7 to 19: mild depression, 20 to 34: moderate depression, and 35 to 60: severe depression. Higher scores indicate increased depressive symptoms.

Time frame:
Baseline, Week 8
Reported as:
Mean · score on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
score on a scaleCentanafadine 400 mgCentanafadine 200 mgPlacebo
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score-0.20 ± 4.150.00 ± 6.56-1.20 ± 4.60
SecondaryNumber of Participants With Suicidality as Measured by Columbia Suicide Severity Rating Scale (C-SSRS) Score

The C-SSRS is a clinician-administered instrument that systematically assess suicidal ideation (SI) and suicidal behavior rating scale. It rates an individual's degree of SI on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent." The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent). The scale identifies specific behaviors ranging from "preparatory acts or behavior" to "suicide" which may be indicative of an individual's intent to complete suicide. Suicidality was reported in this outcome measure, defined as at least 1 occurrence of suicidal ideation or at least 1 occurrence of suicidal behavior for each assessment period.

Time frame:
Week 8
Reported as:
Count of participants · Participants
Number of Participants With Suicidality as Measured by Columbia Suicide Severity Rating Scale (C-SSRS) Score
ParticipantsCentanafadine 400 mgCentanafadine 200 mgPlacebo
Number of Participants With Suicidality as Measured by Columbia Suicide Severity Rating Scale (C-SSRS) Score010

Adverse events

Collected over From first dose of study drug up to 1 week post last dose (Up to 9 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Centanafadine 400 mg0/49 (0%)0/49 (0%)20/49 (40.8%)
Centanafadine 200 mg0/49 (0%)0/49 (0%)12/49 (24.5%)
Placebo0/49 (0%)0/49 (0%)11/49 (22.4%)
Most frequent other events
Most frequent other events
EventCentanafadine 400 mgCentanafadine 200 mgPlacebo
HeadacheNervous system disorders2/497/492/49
DiarrhoeaGastrointestinal disorders5/493/494/49
NauseaGastrointestinal disorders5/491/493/49
Dry MouthGastrointestinal disorders4/492/491/49
ConstipationGastrointestinal disorders3/492/490/49
InsomniaPsychiatric disorders3/492/491/49
RashSkin and subcutaneous tissue disorders3/493/491/49

Baseline characteristics

Randomized analysis set included all participants who were randomized in the double-blind treatment period.

Age, Continuous
Age, Continuous(years)Centanafadine 400 mgCentanafadine 200 mgPlaceboTotal
Age42.5 ± 11.443.3 ± 11.145.6 ± 11.043.8 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Centanafadine 400 mgCentanafadine 200 mgPlaceboTotal
Sex — Female414141123
Sex — Male88824
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Centanafadine 400 mgCentanafadine 200 mgPlaceboTotal
Ethnicity — Hispanic or Latino104418
Ethnicity — Not Hispanic or Latino394545129
Ethnicity — Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Centanafadine 400 mgCentanafadine 200 mgPlaceboTotal
Race — White403237109
Race — Black or African American511925
Race — American Indian or Alaska Native0101
Race — Asian2428
Race — Other2114
Binge Eating Days Per Week
Binge Eating Days Per Week(binge eating days per week)Centanafadine 400 mgCentanafadine 200 mgPlaceboTotal
Mean4.43 ± 1.214.56 ± 1.074.56 ± 1.064.5 ± 1.1
08

Study locations

25 sites
  • NoesisPharma, LLC
    Phoenix, Arizona 85016, United States
  • Southern California Research LLC
    Beverly Hills, California 90210, United States
  • Pharmacology Research Institute - San Fernando Valley
    Encino, California 91316, United States
  • Collaborative Neuroscience Research, LLC
    Garden Grove, California 92845, United States
  • Pacific Clinical Research Management Group LLC
    Upland, California 91786, United States
  • Mountain View Clinical Research, LLC
    Denver, Colorado 80209, United States
  • Clinical Neuroscience Solutions - Jacksonville
    Jacksonville, Florida 32256, United States
  • Miami Dade Medical Research Institute
    Miami, Florida 33176, United States
  • iResearch Atlanta
    Decatur, Georgia 30030, United States
  • Psych Atlanta, PC
    Marietta, Georgia 30060, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Collective Medical Research
    Prairie Village, Kansas 66208, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • St. Charles Psychiatric Associates & Midwest Research Group
    Weldon Spring, Missouri 63304, United States
  • ActivMed Practices and Research - Portsmouth
    Portsmouth, New Hampshire 03801, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Manhattan Behavioral Medicine
    New York, New York 10036, United States
  • Medical Research Network, LLC
    New York, New York 10128, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Craig and Frances Linder Center of Hope
    Mason, Ohio 45040, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Psychiatry + Psychotherapy Partners Austin
    Austin, Texas 78737, United States
  • FutureSearch Trials - Dallas
    Dallas, Texas 75231, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.

Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/

Data sharing details ↗ · clinical-trials.otsuka.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2021 to primary completion in Aug 2022, 7 months.

Results were first posted in Sep 2025, 3 years after primary completion. A results delay was requested in Aug 2023.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2021
First posted
Nov 9, 2021
StartActual
Dec 22, 2021
Primary completionActual
Aug 19, 2022
CompletionActual
Aug 19, 2022
Results delay requested
Aug 25, 2023
Results first posted
Sep 9, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05113953
Responsible party
Sponsor
First posted
Nov 9, 2021
Start date
Dec 22, 2021
Primary completion
Aug 19, 2022
Completion
Aug 19, 2022
Results posted
Sep 9, 2025
Last update
Sep 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Centanafadine

Start the discussion